A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
about
Recent advances of bispecific antibodies in solid tumors.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapyBi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
P2860
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase I trial of the trifunc ...... nts with advanced solid tumors
@en
A phase I trial of the trifunc ...... ts with advanced solid tumors.
@nl
type
label
A phase I trial of the trifunc ...... nts with advanced solid tumors
@en
A phase I trial of the trifunc ...... ts with advanced solid tumors.
@nl
prefLabel
A phase I trial of the trifunc ...... nts with advanced solid tumors
@en
A phase I trial of the trifunc ...... ts with advanced solid tumors.
@nl
P2093
P2860
P1433
P1476
A phase I trial of the trifunc ...... nts with advanced solid tumors
@en
P2093
H Lindhofer
K Steinmetz
O G Ottmann
P2860
P2888
P356
10.1186/S12885-016-2449-0
P407
P577
2016-07-07T00:00:00Z
P6179
1050836814